Cantor Fitzgerald Slashes PT on Eli Lilly and Company (LLY) to $825 From $975

Eli Lilly and Company (NYSE:LLY) is one of the best stocks to invest in for beginners. On August 13, Cantor Fitzgerald analyst Carter Gould lowered the firm’s price target on Eli Lilly and Company (NYSE:LLY) to $825 from $975, keeping an Overweight rating on the shares.

The firm told investors that it believes that the orforglipron Phase 3 obesity data rolling in below expectations, along with the semaglutide benchmarks, create a “show-me-story” around the launch.

It added that a resolution may not be reached until late 2026, supporting the decrease in price target.

Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span oncology, diabetes, immunology, neuroscience, and other therapies.

While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.